NEC has developed a state determination technology that utilizes AI-driven time series data analysis, which can be applied to social infrastructure operation monitoring and other application fields
https://jpn.nec.com/press/201812/20181212_01.html
NEC Corporation (NEC; TSE: 6701) today announced the development of artificial intelligence (AI)-based "time-series data model free analysis technology" that recognizes the status of a rapid, highly accurate system by analyzing time-series data collected from sensors and allowing for searching. Application of this technology will enable the detection of abnormalities, fault diagnosis, and the prediction of breakdowns for important social infrastructure, including plants, roads, bridges, railroads, and vehicles. This technology quickly and accurately recognizes the status (normal, abnormal, signs of abnormality) of a system by using the data collected and accumulated from sensors installed in social infrastructure, such as plant facilities.
https://jpn.nec.com/press/201812/20181212_01.html
https://www.nec.com/en/press/201812/global_20181212_01.html
https://tech.nikkeibp.co.jp/atcl/nxt/column/18/00001/01426/
https://www.sankeibiz.jp/business/news/181213/bsj1812130500001-n1.htm
https://cloud.watch.impress.co.jp/docs/news/1157975.html
NEC and the Kitahara Hospital Group, conducted a technology demonstration at Kitahara Rehabilitation Hospital to create an optimal rehabilitation (rehabilitation) intervention program for patients using AI technology. In this technology demonstration, it was confirmed that NEC's proprietary AI technology "imitation learning technology" to provide support improved the accuracy of the rehabilitation intervention program creation work performed by inexperienced staff by 46%.
https://jpn.nec.com/press/202202/20220228_04.html
https://xtech.nikkei.com/atcl/nxt/column/18/00001/06632/
In collaboration with Renascience Inc., a leading healthcare company in Japan, we have applied our Skill Acquisition Learning (SAiL) engine to diabetes analysis, specifically focusing on predicting the number of medications required at each timing during the treatment process for diabetes patients. SAiL serves as the core technology behind the virtual doctor service for diabetes treatment, particularly benefiting patients in rural areas where access to experienced doctors is limited. Renascience Inc. announced on January 16, 2025, that the diabetes analysis project based on our DM-SAiL technology has successfully passed its first clinical trial in Japan.
Press Release from Renascience Inc. https://www.renascience.co.jp/pipline/aisolution/diabetes/